Hormonal
Aging causes a redistribution of lipids from subcutaneous to visceral adipose tissue, leading to ectopic lipid storage, insulin resistance, and chronic low-grade systemic inflammation.
As you age, your body naturally shifts fat storage from under the skin to around your organs, which increases health risks. This shift is driven by hormonal changes and reduced activity of brown fat. While you can't stop aging, you can counteract these effects through regular exercise, weight management, and potentially medical interventions that improve insulin sensitivity, helping to maintain metabolic health and quality of life.
Aging alters adipose tissue composition and function resulting in insulin resistance and ectopic lipid storage. A reduction in brown adipose tissue activity, declining sex hormones levels, and abdominal adipose tissue expansion occur with advancing years through the redistribution of lipids from the subcutaneous to the visceral fat compartment.
Why this rating
Based on a comprehensive review of multiple studies and established physiological mechanisms.
Source
The Impact of Aging on Adipose Function and Adipokine Synthesis
Peter Mancuso et al. · Frontiers in Endocrinology · 2019
DOI 10.3389/fendo.2019.00137
More from this paper
- Declining brown adipose tissue (BAT) activity with age contributes to reduced energy expenditure and increased obesity risk, mediated by reduced sympathetic output and increased FOXA3 transcription factor.Good
- Aging is associated with an increase in pro-inflammatory adipokines and a decline in anti-inflammatory adipokines, contributing to a chronic state of low-grade systemic inflammation known as 'inflammaging'.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →